Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (Weighted Average) (2016 - 2025)

Editas Medicine (EDIT) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $85.9 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 4.11% to $85.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $85.9 million through Sep 2025, up 4.11% year-over-year, with the annual reading at $82.3 million for FY2024, 8.39% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $85.9 million at Editas Medicine, up from $84.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $85.9 million in Q3 2025, with the low at $66.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $74.9 million, with a median of $71.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 20.95% in 2021, then grew 0.64% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $67.6 million in 2021, then rose by 1.55% to $68.7 million in 2022, then rose by 10.63% to $76.0 million in 2023, then rose by 8.39% to $82.3 million in 2024, then increased by 4.3% to $85.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $85.9 million, $84.4 million, and $83.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.